Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot.

Slides:



Advertisements
Similar presentations
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
Advertisements

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.
WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.
Introduction to HIV Discordant Couple Insemination Deborah J. Anderson, Ph.D. Dept Medicine and Center for AIDS Research Harvard Medical School and Department.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
Myths and Misconceptions
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV status among discordant couples in sub-Saharan Africa: A meta-analysis involving more than 13,000 discordant couples Oghenowede Eyawo, 1 Damien de.
Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.
RESULTS METHODS Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child P. Vernazza 1 I. Brenner 1, I. Graf.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
Global HIV Resistance: The Implications of Transmission
Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2009* * Numbers are based on reports received rather than children seen to.
Genital secretions from HIV-1 infected women on effective antiretroviral therapy contain high drug concentrations and low amounts of cell-free virus Anandi.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to May 2005.
Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
HIV INFECTION D - preventive Medicine. HIV INFECTION LEARNING OBJECTIVES  Describe the pathophysiology of HIV infection.  Describe the principal mechanisms.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Edward Mills PhD, Associate Professor, Faculty of Health Sciences University of Ottawa AIDS Mortality Among Men in Africa: An overview of the evidence.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
HIV-1 dynamics Perelson et.al. Science 271:1582 (1996) Infected CD4 + lymphocytes Uninfected, activated CD4 + lymphocytes HIV-1 t 1/ days t 1/2.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
Resistance Mutations Before and After Tenofovir Regimen Failure in HIV-1 Infected Patients. £ Background: Except for the K65R mutation, little is known.
PhD We knew nothing about the set-point viral loads. What was unknown about HIV-1 infection before this paper was published in 2007? 1.Virus density.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modeling approach Dawn K.
Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments S. Fourati 1, S. Lambert-Niclot 1, C. Soulie 1, M.
Mean HIV viral load among resident cases and undiagnosed in Oregon Jeff Capizzi, Epidemiologist Sean Schafer, HIV/STD/TB Medical Epidemiologist Lea Bush,
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Evaluation of two techniques for viral load monitoring on DBS ANRS project Phase I - Laboratory.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Risk of Sexual Transmission under HAART Background information on Swiss statement Pietro Vernazza President EKAF- Swiss Federal Commission on AIDS.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Phar. Nhat Mang/ Roche Vietnam
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
New Developments in HIV Kerri Howley Coordinator – The Green Room
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Herpes Simplex Virus Type 2 infection among U.S. military service members: Public Health Implications and Opportunities for HIV Prevention Christian T.
L’ INTRODUZIONE DI RALTEGRAVIR IN TERAPIA RIDUCE A LIVELLI NON DOSABILI LA VIRAL LOAD SEMINALE IN “SEMINAL SUPER SHEDDERS” HIV+ Implicazioni per la trasmissione.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
Research to design community based prevention IAS Satellite – July 17, 2011 “Controlling the HIV epidemic – The promise of ARV-based prevention”
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Switch to PI/r monotherapy
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Emory University School of Medicine Department of Medicine
RAL + MVC + DRV/r + TDF-FTC
INPUT OF PMTCT TO ZERO NEW HIV INFECTION-CAMPAIGN IN RWANDA: Case of MUHIMA District Hospital By NTACYABUKURA Blaise, University of Rwanda, college of.
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
Sarah Hawkes, Paz Bailey G, Sternberg M, Lewis DA and Puren A
Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II
INFERTILITY TREATMENT BY IN VITRO FERTILIZATION OR INTRA-CYTOPLASMIC SPERM INJECTIONS IN CHRONIC HIV-1 SERO-DIFFERENT COUPLES : DO WOMEN HIV INFECTION.
PHARMACOTHERAPY III PHCY 510
U=U Guidance for Implementation in Clinical Settings
Presentation transcript:

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma Marcelin AG 1, Tubiana R 1, Lambert-Niclot S 1, Lefebvre G 1, Dominguez S 1, Bonmarchand M 1, Vauthier-Brouzes D 1, Marguet F 1, Peytavin G 2, Poirot C 1 and the Pitié-Salpêtrière AMP à risque viral Study Group 1 Hôpital Pité-Salpêtrière, Université Pierre et Marie Curie, Paris, France 2 Hôpital Bichat-Claude-Bernard, Université Denis Diderot, Paris, France

Background (I)  Recently, the Swiss Federal Commission for HIV/AIDS stated that a seropositive individual, with no other sexual transmitted disease (STD), under antiretroviral treatment and with an undetectable HIV-1 plasma viral load (< 40 copies/ml) for at least 6 months, does not sexually transmit HIV.  However, using a model-based analysis, it has been shown that the risk of HIV transmission in heterosexual partnerships in the presence of effective treatment is low but non-zero and that the transmission risk in male homosexual partnerships is higher over repeated exposures 1.  Indeed, studies have shown that there is a strong relation between HIV plasma viral load and heterosexual transmission rates Wilson et al. Lancet Quinn et al. NEJM 2000.

Background (II)  However, HIV plasma viral load might not always reflect HIV replication levels in semen and some factors could increase the risk of transmission, such as:  Incomplete adherence  Variable drug penetration in compartments?  Other STDs  The aim of this study was to evaluate the residual HIV-1 RNA shedding in semen from patients who were enrolled in an assisted reproductive technology program (ART).

Methods (I)  Since 2002, our clinical centre has managed HIV-1 serodiscordant couples within the male partner is infected and not the female to allow pregnancies with assisted reproduction techniques (ART) in order to:  Avoid the risk of HIV sexual transmission  In some cases, to treat infertility  For this purpose, before ART, sperm is “washed” and frozen until virological testing has shown the absence of HIV RNA detection.

Sperm Density gradient centrifugation 90% fraction Spermatozoa Seminal plasma 90% 10% Washing centrifugation HIV-1 ARN detection Washed Spermatozoa HIV-1 ARN detection Freezing Until ART

Methods (II)  145 HIV-1 infected men attending the Pitié-Salpêtrière Hospital in the multidisciplinary ART program provided 264 paired blood and semen samples between January 2002 and January  The Cobas Taqman HIV-1 Assay was used to quantify HIV-1 RNA in blood and in seminal plasma as previously described with a limit of quantification of 40 copies/ml in blood and 200 copies/ml in seminal plasma.  ARV pharmacological measurements were performed in blood and seminal plasma.

Results (I)  Among the total 264 paired samples:  32 blood samples had HIV-1 RNA > 40 copies/ml Median HIV RNA = 6325 copies/ml (range = 222 – cp/ml)  16 seminal samples had HIV-1 RNA > 200 copies/ml Median HIV RNA = 1770 copies/ml (range = 255 – cp/ml)  234/264 paired samples were concordant:  225 samples with undetectable HIV-1 RNA both in blood and semen (85.3 %)  9 samples with detectable HIV-1 RNA in blood and semen (3.4%)

Results (II)  30/264 paired samples were discordant:  23 with detectable HIV-1 RNA in blood although the seminal viral load was undetectable  7 with detectable HIV-1 RNA in seminal plasma although the blood viral load was undetectable

Results (III)  These 7 discordant paired samples corresponded to 7 distinct patients.  All these patients were under stable HAART with an undetectable HIV-1 RNA in blood plasma for at least 6 months and had no other STDs that are systematically screened in the program.  Among these 7 patients, 6 had an undetectable concordant result in blood and semen in at least one other time point during follow up.

Blood plasma Seminal plasma

Patient Age (ys) CD4 (cell/mm 3 ) HIV-1 RNA (cp/mL) Circular cells (10 6 /mL) ARV Drug concentration (ng/mL) bloodSeminalBloodSeminal < ZDV+3TC+IDV/rNA < TC EFV LPV/r <10 < < ZDV 3TC LPV/r <10 <30 < < < TDF FTC ATV 81 <10 <30 87 <10 < < ZDV 3TC IDV/r < < < FTC+ATV/rNA < TDF FTC EFV 15 < <10 When antiretroviral drugs such as lamivudine, tenofovir and indinavir were present in blood they were also detected in semen

Conclusions (I)  These results show that 5% of patients had detectable HIV-1 RNA in seminal plasma although they had concomitantly undetectable HIV-1 RNA in blood while they were under effective HAART and with no other STDs.  This does not seem to be related to a specific type of ARV treatment.  In these cases, HIV-1 RNA in seminal plasma is comprised between 255 to 1230 copies/ml.  This study confirms that HIV RNA shedding is intermittent in semen over time and that the rate of 5% should be considered as a low estimation of this phenomenon.

Conclusions (II)  Although, the presence of HIV-1 RNA does not mean necessarily infectious viruses, this result suggests that cell free virus can be still present in semen despite fully active ARV treatment.  These results should be taken into account in public health messages.  Indeed, while effective antiretroviral therapy is likely to substantially reduce HIV transmission at a population level, residual HIV RNA shedding can occur.

Conclusions (III)  Longitudinal studies should be conducted to measure more precisely the frequency and quantity of genital HIV shedding like those previously conducted for HSV.  Search for any relationship between the type of ARV use and the occurrence of viral shedding in a larger cohort of patients.

Acknowledgments  ART multidisciplinary group  Infectious Disease : R. Tubiana, S. Dominguez, C. Katlama  Internal Medicine: M. Bonmarchand, A. Simon  Gynecology : G. Lefebvre, D. Vauthier, M. Dommergues  Reproductive biology : C. Poirot  Virology : V. Thibault, V. Calvez  Hepatology: P. Lebray  Pediatrics : I. de Montgolfier  Psychiatry : O. Rosenblum  This study was supported in part by ANRS